Board and Management

Board and Management

Graham Kelly - Managing Director and Chief Executive Officer

BSc (Vet) (Hons, BVSc (Hons), PhD

Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, contributing through research in the areas of organ recovery for transplantation and liver transplant surgery. The increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the causes of that phenomenon, and in turn, to the broader issue of the link between diet and the incidences of certain cancers. The latter area of research led to a research interest in dietary isoflavones and their role in human health.

Graham developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London’s AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.

In 2011, Graham joined private biotechnology company, Triaxial Pharmaceuticals Pty Ltd, as Executive Chairman. Concerned at the direction being taken by the Novogen Board in having stripped all assets from the Company and leaving it without a business, Graham engineered a reverse takeover of Novogen Ltd by Triaxial in December 2012 and set about rebuilding the Company. He remained as CEO and Executive Chairman of Novogen until June 2015 and was responsible for in-licensing that Company’s anti-tropomyosin drug technology, for establishing a joint venture company with Yale University, and for establishing a solid financial base.

In early-2012, Graham addressed the matter of the transport of isoflavones in the blood of humans, conducting formulation studies in a private capacity that led shortly thereafter to the concept behind NOX66. After leaving Novogen in 2015, Graham established private biotechnology company Noxopharm Pty Ltd in order to commercialise NOX66.


Peter Marks - Non-Executive Chairman

Peter brings over 30 years’ experience in corporate advisory, investment banking and director/advisory roles to the Board. With several leading firms, Peter’s corporate skills lie in capital raising for pre-IPO and listed companies, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, US & Israel.

Over this period Peter has been involved in a very broad range of transactions, with a special focus in the life sciences, biotechnology, medical technology and high tech segments. He has been a Director and/or Chairman of several public companies. He currently is a Director of Prana Biotechnology Ltd (ASX & Nasdaq listed) since 2005, Chairman of Armadale Capital Plc (AIM listed) since 2009, and Non-Executive Director of Emefcy Group Limited (ASX listed) since 2015.

Peter provides strategic and corporate advice at various stages of technology commercialisation for companies to transition to an operating entity, and helps facilitate significant commercial transactions to create shareholder value.

Peter holds a Bachelor of Economics, Bachelor of Laws and a Graduate Diploma in Commercial Law from Monash University, Australia. He also holds an MBA from the University of Edinburgh, Scotland.


Ian Dixon

Ian Dixon - Non-Executive Director

MBA, PhD

Ian has a PhD in biomedical engineering from Monash University and an MBA from Swinburne University. Ian initially qualified as a mechanical engineer in the early 1980s and then also completed a course in electronics engineering. Ian worked in R&D in manufacturing automation and product development in Melbourne and also Cambridge UK before establishing his first business in 1987 in the telecommunications power field. From 1987 to 1995 Ian grew two successful export-oriented manufacturing and R&D businesses – both purchased by public companies.

In 1995 Ian joined Vision Systems as the Director of the Product Group within the Invetech business unit, and managed the team responsible for developing innovative diagnostic, pathology automation and security system products. Ian later left Vision Systems and continued being active in the product and technology development scene as an investor and executive.

In 2002 Ian was the co-founder of Genscreen Pty Ltd, a biotechnology incubator with a particular focus on cancer therapeutics. Amongst a number of projects, Genscreen developed a novel first-in-class anticancer drug based on anti-tropomyosin technology which was outlicensed to Novogen Ltd in 2013. During this time Ian also had experience in the regenerative medicine and cancer immunotherapy fields as a non-executive director of Cell Therapies Ltd.

In 2011 Ian co-founded Cynata Inc and helped to progress the commercialisation of what has become the Cymerus technology of Cynata Therapeutics Ltd (ASX-CYP).

Ian brings to the Board an extensive entrepreneurial background in founding, building and running public companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.


David Franks

David Franks - Company Secretary

B.Ec ( Finance and Accounting)

David is a Chartered Accountant, Fellow of the Financial Services Institute of Australasia, Justice of Peace and Registered Tax Agent, with over 20 years’ experience as a Director and Company Secretary of numerous publicly listed entities. He holds a Bachelor of Economics (Finance and Accounting) from Macquarie University. David is an experienced Company Secretary and Director of listed and unlisted public companies and principal of Franks and Associates Pty Limited (Chartered Accountants). David is currently Company Secretary for the following public companies: Armidale Investment Corporation Limited, Elk Petroleum Limited, JCurve Solutions Limited, Pulse Health Limited, Tomorrow Entertainment Limited, White Energy Company Limited and White Energy Technology Limited.